# A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

> **NCT05865730** · PHASE2 · RECRUITING · sponsor: **EverImmune** · enrollment: 122 (estimated)

## Conditions studied

- Carcinoma, Renal Cell
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **OTHER:** Live Bacterial Product - Akkermansia muciniphila

## Key facts

- **NCT ID:** NCT05865730
- **Lead sponsor:** EverImmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-01
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05865730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05865730, "A Study of Oncobax®-AK in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05865730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*